BridgeBio Pharma, Inc. (BBIO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

BridgeBio established a $500 million at-the-market (ATM) offering program with Goldman Sachs and Leerink Partners, providing flexible capital raising capability without immediate dilution, suggesting the company is preparing for potential liquidity needs or strategic investments.
The company terminated its previous equity distribution agreement from May 2023 and replaced it with a new one, indicating a strategic refresh of financing arrangements after approximately 3 years, potentially reflecting improved market conditions or evolving capital strategy.
With a 3.0% commission structure on gross proceeds, the ATM offering provides cost-efficient capital access compared to traditional equity financing methods, allowing the company to raise funds opportunistically based on market conditions and operational needs.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-30

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for its product candidate BBP-418 to treat individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare genetic disorder.
The submission of the NDA represents a significant milestone for the company as it moves towards potential regulatory approval and commercialization of BBP-418 for this patient population with limited treatment options.
The successful NDA submission signals BridgeBio's progress in its pipeline development and its commitment to addressing unmet medical needs in rare genetic diseases.

Filed: 2026-02-24

BridgeBio Pharma reported its Q4 2025 and full-year 2025 financial results, providing an update on its recent business activities.
The company did not provide any financial guidance or updates on its key pipeline programs, which could be a concern for investors.
The absence of material news or catalysts in this 8-K filing suggests it may be a routine quarterly update without significant developments.

Filed: 2026-02-12

BridgeBio Pharma reported positive Phase 3 topline results for its oral infigratinib treatment, which achieved statistically significant improvements in body proportionality for patients with achondroplasia.
The successful Phase 3 trial represents a major milestone for BridgeBio's pipeline and could potentially lead to regulatory approval and commercialization of this new therapy.
Investors may view this as a positive development for the company, as it demonstrates BridgeBio's ability to advance its drug candidates through late-stage clinical trials and achieve meaningful clinical outcomes.

Filed: 2026-01-21

BridgeBio Pharma issued $632.5 million in 0.75% Convertible Senior Notes due 2033, with the net proceeds used to repay existing convertible notes and for general corporate purposes.
The new convertible notes are convertible into cash, shares of BridgeBio's common stock, or a combination, at BridgeBio's election, with an initial conversion price of $110.58 per share.
BridgeBio also intends to use $82.5 million of cash to repurchase 1,081,825 shares of its common stock from certain purchasers of the notes in privately negotiated transactions.

Filed: 2026-01-12

BridgeBio Pharma reported preliminary Q4 2025 and full-year 2025 financial results, indicating strong net product revenue growth and a healthy cash position to support ongoing operations.
The company is making progress with its clinical development pipeline, including the new antibody depleter program for ATTR-CM and expected regulatory filings for BBP-418 and encaleret.
BridgeBio continues to execute on its strategy of rapidly advancing its diverse portfolio of rare disease therapies, positioning the company for potential future value creation.

Other reports for BridgeBio Pharma, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.